AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Cytosolic carboxypeptidase 3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8NEM8

UPID:

CBPC3_HUMAN

Alternative names:

ATP/GTP-binding protein-like 3; Protein deglutamylase CCP3

Alternative UPACC:

Q8NEM8; B7Z827; Q9H965

Background:

Cytosolic carboxypeptidase 3, also known as ATP/GTP-binding protein-like 3 and Protein deglutamylase CCP3, is a pivotal enzyme in cellular function. It specializes in the deglutamylation of tubulin and various non-tubulin proteins, including MYLK, by removing polyglutamate side chains. This process is crucial for the regulation of tubulin, a key component of the cytoskeleton, affecting cell shape, division, and motility.

Therapeutic significance:

Understanding the role of Cytosolic carboxypeptidase 3 could open doors to potential therapeutic strategies. Its unique enzymatic activity in protein modification and cellular regulation highlights its potential as a target in diseases where these processes are dysregulated.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.